The Influence of Free Hemoglobin and Bilirubin on Heparin Monitoring by Activated Partial Thromboplastin Time and Anti-Xa Assay

被引:58
|
作者
Kostousov, Vadim [1 ,3 ]
Nguyen, Kim [3 ]
Hundalani, Shilpa G. [2 ,4 ]
Teruya, Jun [1 ,2 ,3 ]
机构
[1] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Texas Childrens Hosp, Div Transfus Med & Coagulat, Houston, TX 77030 USA
[4] Texas Childrens Hosp, Dept Pediat, Sect Neonatol, Houston, TX 77030 USA
关键词
EXTRACORPOREAL MEMBRANE-OXYGENATION; COAGULATION MANAGEMENT; CENTRIFUGAL PUMPS; HEMOLYSIS; ANTICOAGULATION; INTERFERENCE;
D O I
10.5858/arpa.2013-0572-OA
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-Elevated free hemoglobin (Hb) and bilirubinemia complicate extracorporeal membrane oxygenation and could affect unfractionated heparin (UH) therapy monitoring by anti-Xa assay and activated partial thromboplastin time (aPTT). Objectives.-To compare in vitro response of anti-Xa and aPTT assays to UH in samples with artificial hyperbilirubinemia and hyperhemoglobinemia and to estimate if this interference is also observed in vivo in pediatric extracorporeal membrane oxygenation. Design.-Measurement of aPTT and anti-Xa activity in plasma spiked with UH and increased concentration of free Hb and/or conjugated bilirubin. All samples with antiXa activity, antithrombin, free Hb, and bilirubin determination and infused dose of UH from inpatients on extracorporeal membrane oxygenation were extracted from the clinical patient database and analyzed. Results.-Each increment of free Hb by 100 mg/dL significantly shortened aPTT, whereas an increment of bilirubin by 6 mg/dL caused significant prolongation of aPTT and stepwise increase of free Hb and/or bilirubin in plasma decreased anti-Xa activity by 0.03 to 0.05 IU/mL. Extracorporeal membrane oxygenation samples with free Hb 50 mg/dL or greater had significantly lower anti-Xa activity compared with normal ones: 0.33 (0.25-0.42) versus 0.4 (0.31-0.48) IU/mL (P = .01), despite the identical UH infusion and similar antithrombin activity. Moderate increase of free Hb by 59 mg/dL was associated with absolute decrease of anti-Xa activity by 0.07 IU/mL. Conclusions.-Activated partial thromboplastin time and anti-Xa assay are affected by elevated level of free Hb and/or bilirubin in the presence of UH, and lower antiXa activity is noted in extracorporeal membrane oxygenation patients with elevated free Hb. Severe hemolysis and/or hyperbilirubinemia could compromise UH monitoring based on these assays.
引用
收藏
页码:1503 / 1506
页数:4
相关论文
共 50 条
  • [21] Comparison of Antifactor Xa and Activated Partial Thromboplastin Time Monitoring for Heparin Dosing in Vascular Surgery Patients: A Single-Center Retrospective Study
    Rizk, Elsie
    Wilson, Allison D.
    Murillo, Michelle U.
    Putney, David R.
    THERAPEUTIC DRUG MONITORING, 2018, 40 (01) : 151 - 155
  • [22] Partial thromboplastin time is more predictive of bleeding than anti-Xa levels in heparinized pediatric patients after cardiac surgery
    Oladunjoye, Olubunmi O.
    Sleeper, Lynn A.
    Nair, Asha G.
    Trenor, Cameron C., III
    VanderPluym, Christina
    Kheir, John N.
    Emani, Sitaram M.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2018, 156 (01) : 332 - +
  • [23] Description of anti-Xa monitoring practices during low molecular weight heparin use
    Lin, Albert
    Vazquez, Sara R.
    Jones, Aubrey E.
    Witt, Daniel M.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 48 (04) : 623 - 628
  • [24] Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer
    Kreuziger, Lisa Baumann
    Streiff, Michael
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 206 - 207
  • [25] Interference in the anti-Xa heparin activity assay due to hemolysis and icterus during pediatric extracorporeal life support
    Khan, Jenna
    Chandler, Wayne L.
    ARTIFICIAL ORGANS, 2019, 43 (09) : 880 - 887
  • [26] Anti-factor Xa and activated partial thromboplastin time strategies for unfractionated heparin dosing after HeartMate 3 left ventricular assist device implantation
    Feng, Iris
    Kurlansky, Paul A.
    Powley, Tanner R.
    Hynds, Melissa A.
    Yang, Christine G.
    Eisenberger, Andrew
    Hastie, Jonathan M.
    Sutherland, Lauren D.
    Yuzefpolskaya, Melana
    Colombo, Paolo C.
    Sayer, Gabriel T.
    Uriel, Nir Y.
    Naka, Yoshifumi
    Takeda, Koji
    ARTIFICIAL ORGANS, 2024, : 497 - 507
  • [27] Anti-Xa Assay Monitoring Improves the Precision of Anticoagulation in Venovenous Extracorporeal Membrane Oxygenation
    Hla, Teddy Tun Win
    Christou, Silvana
    Sanderson, Barnaby
    Hanks, Fraser
    Cameron, Lynda
    Camporota, Luigi
    Doyle, Andrew J.
    Retter, Andrew
    ASAIO JOURNAL, 2024, 70 (04) : 313 - 320
  • [28] Propofol-induced interference with activated partial thromboplastin time-based monitoring of therapeutic heparin anticoagulation
    Negaard, Briana J.
    Hobbs, Ryan
    Frye, Jared R.
    Merrill, Anna E.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2023, 80 (07) : 445 - 451
  • [29] Laboratory Assessment of Unfractionated Heparin (UFH) with Activated Clotting Time (ACT) and Anti-Xa Activity during Peripheral Arterial Angiographic Procedure
    Helin, Tuukka
    Tirri, Tomi
    Korkala, Heidi
    Lappalainen, Kimmo
    Joutsi-Korhonen, Lotta
    DIAGNOSTICS, 2023, 13 (08)
  • [30] Anti-Xa level monitoring of low-molecular-weight heparin during intermittent venovenous hemofiltration
    Xu, Lengnan
    Sun, Ying
    Wang, Songlan
    Li, Chuanbao
    Mao, Yonghui
    ANNALS OF HEMATOLOGY, 2023, 102 (08) : 2251 - 2256